Chris Davies

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 159 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Positive Breast Cancer +18

The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis

Chris De Savi, Andrew R. Pape, John G. Cumming et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 20 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Anti-inflammatory +9

Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis

Chris De Savi, Andrew R. Pape, Yvonne Sawyer et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 16 citations · Full text

Anti-inflammatory, Medicine, Osteoarthritis +3